楼主: bigfoot0518
1463 0

[外行报告] 瑞士信贷:美国制药行业研究报告2009年1月 [推广有奖]

已卖:2563份资源

学术权威

70%

还不是VIP/贵宾

-

威望
10
论坛币
10441579 个
通用积分
7.0590
学术水平
1222 点
热心指数
923 点
信用等级
1220 点
经验
65985 点
帖子
2052
精华
21
在线时间
405 小时
注册时间
2008-12-11
最后登录
2021-8-16

楼主
bigfoot0518 发表于 2009-1-23 10:28:00 |AI写论文

+2 论坛币
k人 参与回答

经管之家送您一份

应届毕业生专属福利!

求职就业群
赵安豆老师微信:zhaoandou666

经管之家联合CDA

送您一个全额奖学金名额~ !

感谢您参与论坛问题回答

经管之家送您两个论坛币!

+2 论坛币

US Major Pharmaceuticals
PRE RESULTS COMMENT
Price Increases Should Outweigh Currency
Headwinds in 4Q 2008

The defensive nature of the pharma industry provided some support for the
group during the volatile 4Q 2008, with our names down “only” 6.7% as
opposed to the S&P that was down 22.2%. Heading into 4Q 2008 earnings
these defensive traits should allow for continued year-over-year earnings
growth for most of our names (MRK being the notable exception). Much of
the growth continues to be generated by significant price increases, however,
which we do not see as sustainable over the coming years.

Currency concerns have eased to some degree but still present a significant
headwind to all of our names this quarter, given the 9.1% annual and 12.5%
sequential change in the US dollar to Euro relationship during the quarter.

Our most notable differences to consensus include SGP (+$0.02, +6.9%)
and WYE (+$0.02, +2.0%). SGP is up 40% over last 3 months and so a
strong quarter may be followed by profit-taking, providing an entry point for
longer-term investors. WYE may be a name to buy pre-quarter as results
should beat and 2009 guidance could lead to positive revisions.

Post quarter, JNJ may offer a short-term trading opportunity. The stock is
down 11% over the last 3 months as investors have been bracing for 2009
guidance, given competitive &/or economic pressure on all 3 Divisions
(Pharma, MDD & Consumer). We expect guidance to offer a wide range,
with the bottom beneath consensus. After 2009 is better understood we
think the stock could be an attractive trade in the sense that it has limited
downside and to generalists may appear more defensive than other options.

In advance of 4Q 2008 earnings, we have fine-tuned our company and
market models with resulting EPS changes. Significant changes to the
company models are explained in each company’s section.

ABT 2008 EPS: old $3.35, new $3.34, and 2009 EPS: old $3.70, new $3.69.

BMY 2008 EPS: old $1.69, new $1.70, and 2009 EPS: old $2.08, new $1.96.

JNJ 2008 EPS: old $4.55, new $4.54, and 2009 EPS: old $4.58, new $4.56.

LLY 2008 EPS: old $4.01, new $3.98, and 2009 EPS: old $4.17, new $4.18.

MRK 2008 EPS: old $3.28, new $3.29, and 2009 EPS old $3.19, new $3.25.

PFE 2008 EPS: old $2.37, new $2.36, and 2009 EPS: old $2.45, new $2.44.

SGP 2008 EPS: old $1.67, new $1.68, and 2009 EPS: old $1.71, new $1.73.

WYE 2008 EPS: remains at $3.56, and 2009 EPS: old $3.77, new $3.76.

288267.pdf (953.61 KB, 需要: 500 个论坛币)


二维码

扫码加我 拉你入群

请注明:姓名-公司-职位

以便审核进群资格,未注明则拒绝

关键词:行业研究报告 制药行业 研究报告 瑞士信贷 行业研究 美国 研究报告 行业 信贷 瑞士

您需要登录后才可以回帖 登录 | 我要注册

本版微信群
jg-xs1
拉您进交流群
GMT+8, 2025-12-22 21:14